QuidelOrtho Surges on Strong Q2 Earnings and Expanding Margins

QuidelOrtho Corporation’s Strong Second-Quarter Performance

QuidelOrtho Corporation delivered impressive results for the second quarter of 2025, with adjusted earnings per share (EPS) reaching 12 cents, significantly outperforming the Zacks Consensus Estimate of breakeven. This marks a substantial improvement from the 7 cents loss recorded in the same period the previous year. The company's adjusted EPS figure reflects the impact of various expenses, including amortization of intangibles and acquisition-related costs.

GAAP losses per share for the quarter were $3.77, compared to $2.20 per share in the year-earlier period. Despite this, the company's overall financial performance showed resilience and growth in several key areas.

Revenue Breakdown and Performance Highlights

QuidelOrtho reported total revenues of $613.9 million for the second quarter of 2025, which represents a 3.6% decline on a reported basis and a 3.9% decrease at constant exchange rates (CER). However, the figure exceeded the Zacks Consensus Estimate by 0.4%, indicating positive market sentiment.

The company's revenue streams are divided into two main categories: Respiratory and Non-Respiratory. In the second quarter, Respiratory revenues totaled $46.7 million, reflecting a 19.5% drop on a reported basis and a 19.9% decrease at CER. Non-Respiratory revenues stood at $567.2 million, down 2% on a reported basis and 2.2% at CER.

Shares of QuidelOrtho rose nearly 12.8% in after-market trading following the release of the quarterly results. Despite this gain, the stock has declined 46.8% year-to-date, while the broader industry has seen a 4.9% increase and the S&P 500 has risen 7.4%.

Business Unit Performance

QuidelOrtho operates through five business units: Labs, Immunohematology, Donor Screening, Point of Care, and Molecular Diagnostics. The company has restructured its operations, consolidating the former Transfusion Medicine unit into Immunohematology and Donor Screening.

Labs revenues reached $369.7 million in the second quarter, up 4.4% on a reported basis and 4.6% at CER. Immunohematology revenues were $132.3 million, showing a 4.3% increase on a reported basis and a 2.9% rise at CER. Donor Screening revenues dropped sharply to $13.3 million, declining 61.2% on a reported basis and 61.4% at CER. Point of Care revenues fell to $93 million, down 20.6% on a reported basis and 20.9% at CER. Molecular Diagnostics revenues increased to $5.6 million, up 27.3% on a reported basis and 24.2% at CER.

Geographical Revenue Trends

Geographically, QuidelOrtho generates revenue from North America, Europe, the Middle East, and Africa (EMEA), China, and Other regions (including Latin America, Japan, and other Asia-Pacific markets).

North America revenues declined to $310.7 million, down 11.3% on a reported basis and 11.6% at CER. EMEA revenues rose to $87.3 million, reflecting a 7.6% increase on a reported basis and a 3.3% increase at CER. China revenues reached $83.4 million, up 2.2% on a reported basis and at CER. Revenues from Other regions climbed to $132.5 million, increasing 6.7% on a reported basis and 9.6% at CER.

Margin Improvements and Financial Position

QuidelOrtho saw an expansion in adjusted gross margin to 45.7%, up 150 basis points year over year, despite a 0.4% decline in adjusted gross profit to $280.5 million. Adjusted selling, marketing, and administrative expenses fell 5.9% to $170 million, while adjusted research and development expenses decreased 18.6% to $45.2 million. Adjusted operating expenses dropped 8.9% to $215.2 million, leading to an adjusted operating profit of $60.2 million, a 67.7% improvement from the prior-year quarter. Adjusted operating margin expanded 420 basis points to 9.8%.

QuidelOrtho ended the second quarter of 2025 with cash and cash equivalents of $151.7 million, up from $127.1 million at the end of the first quarter. Total debt, including short-term debt, was $2.61 billion, compared to $2.49 billion at the end of the first quarter. Cumulative net cash provided by operating activities was $18.8 million, versus net cash used in operating activities of $98.6 million a year ago.

Full-Year Guidance and Strategic Outlook

QuidelOrtho has reiterated its full-year guidance for 2025, projecting total revenues between $2.60 billion and $2.81 billion, with the Zacks Consensus Estimate at $2.72 billion. The company expects stable growth across most business lines, particularly in Labs and Immunohematology. In China, despite early second-quarter softness due to delayed shipments related to evolving tariffs, full-year growth is still expected to be in the mid- to high-single digits.

For the full year, QuidelOrtho anticipates respiratory revenues to range between $110 million and $140 million, assuming a summer spike consistent with past trends. Adjusted EPS is projected to fall between $2.07 and $2.57, with the Zacks Consensus Estimate at $2.39.

Management Insights and Future Outlook

Management highlighted strong recurring revenue from long-term contracts and an expanding installed base of integrated and automated lab systems. The company also emphasized continued progress in commercial and operational improvements, with a 330-basis point year-over-year improvement in adjusted EBITDA margin and a 271% increase in adjusted diluted EPS.

QuidelOrtho remains focused on driving incremental margin improvements through cost-reduction actions, including indirect procurement efforts and manufacturing consolidation. The company aims to achieve mid- to high-20% EBITDA margins by mid-2027.

Despite ongoing challenges, such as the wind-down of the Donor Screening business and reduced demand in respiratory testing, QuidelOrtho remains optimistic about its long-term prospects in China, citing low market penetration and a strategic focus on stat labs as key advantages.

Key Stock Picks and Market Comparison

QuidelOrtho currently carries a Zacks Rank of #3 (Hold). Some better-ranked stocks in the medical space that have announced quarterly results include Medpace Holdings, Inc. (MEDP), West Pharmaceutical Services, Inc. (WST), and Boston Scientific Corporation (BSX).

Medpace Holdings, with a Zacks Rank of #1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating estimates by 3.3%. Its revenues of $603.3 million surpassed the consensus mark by 11.5%. West Pharmaceutical Services reported second-quarter 2025 adjusted EPS of $1.84, exceeding estimates by 21.9%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating estimates by 4.2%.